{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973745",
  "id": "02973745",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250729",
  "time": "0937",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7w4hpvk67h5.pdf",
  "summary": "**Key Highlights (Clinical Trial Announcement):**  \n- **SNT-9465 Phase 1a/b trial** commenced for **hypertrophic scars** (first participant dosed).  \n- **Trial focus**: Safety/tolerability (Phase 1a), then efficacy in scar improvement (Phase 1b).  \n- **Results expected H1 2026**, supporting FDA Investigational New Drug (IND) application.  \n- **Market potential**: Hypertrophic scars/keloids represent ~$3.5bn addressable market.  \n- **Differentiation**: Potential first pharmacological treatment vs. invasive current therapies (laser/steroids).  \n\n*No material capital markets or trading-specific information identified.*",
  "usage": {
    "prompt_tokens": 1764,
    "completion_tokens": 148,
    "total_tokens": 1912,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:40:46.362289"
}